Category: Pharma

Merck & Co. (MRK) reported its second-quarter 2026 financial results, delivering a performance that simultaneously showcased the unmatched commercial power of…

Pfizer Inc. (PFE) reported its second-quarter 2026 financial results, delivering a performance that underscored the company’s successful pivot away from its…

One of the most overlooked healthcare developments of the last forty-eight hours came not from a drug trial, a reimbursement…

The most interesting healthcare-operations development of the last forty-eight hours was LataMed AI and FARMASER entering a memorandum of understanding…

The most interesting biotech development of the last forty-eight hours is not a drug approval or a late-stage efficacy surprise.…

The most important biotech development of the last forty-eight hours is not another deal, a manufacturing expansion, or a platform…

For decades, the drug industry treated regulation and manufacturing as sequential problems. Companies developed an asset, built or secured production…

For years, the biopharma industry treated global clinical-trial geography as an execution question. Companies went where patient recruitment was faster,…

The most interesting biotech deal of the day is not important because of its size alone. It is important because…

Biotech investors are used to thinking about drug pricing as a domestic argument. The traditional battle lines are familiar: governments…

How a surge in targeted mid-sized acquisitions is reshaping oncology and metabolic pipelines as major drugmakers brace for a revenue…